Abstract:Chimeric antigen receptor T cell (CAR-T) therapy is a late-model of immune cell therapy that has been shown to be effective in refractory/recurrent B-cell leukemia and lymphoma. Compared with the traditional anti-tumor methods, CAR-T cell therapy has the advantages of higher specificity, stronger lethality and longer-lasting efficacy. Although CAR-T cells have made significant progress in the treatment of hematologic malignancies, diverse difficulties remain in the treatment of solid tumors, including immune escape due to tumor antigen heterogeneity, preventing entry or limiting the persistence of CAR-T cells by physical or cytokine barriers and along with other immunosuppressive molecule and cells in the tumor microenvironment (TME). Otherwise, the intracellular signaling of CAR also impact on CAR-T cells persistence. Appropriate modification of intracellular costimulatory molecular signal in the structure of CAR or coexpression of CAR and cytokines can provide a way to enhance CAR-T cells activity. Additionally, CAR-T cells dysfunction due to T cell exhaustion is associated with multi-factors, especially transcription factors, such as c-Jun, NR4A. Engineering CAR-T cells to coexpress or knockout transcription factors in favor of T<sub>CM</sub> memory CAR-T cells differentiation was proved to prolonged the survival of CAR-T cells. Finally, combination of CAR-T cells with oncolytic viruses, nanoparticles or immune checkpoint inhibitors provides an effective measure to improve CAR-T cells function. Here, we discuss all of these advances and challenges and review promising strategies for treating solid tumors. In particular, we also highlight that CAR-T cells have enormous potential to be used in combination with other immunotherapies.

Development of CAR T cells designed to improve antitumor efficacy and safety

Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

CAR-T cell therapy: current limitations and potential strategies

Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies

Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes

Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors

Engineering strategies to overcome the current roadblocks in CAR T cell therapy

Tuning CAR T-cell therapies for efficacy and reduced toxicity

CAR T Cells: A Snapshot on the Growing Options to Design a CAR

New development in CAR-T cell therapy

Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy

Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility

Tuning the performance of CAR T cell immunotherapies

Fully equipped CARs to address tumor heterogeneity, enhance safety, and improve the functionality of cellular immunotherapies

Engineering enhanced chimeric antigen receptor-T cell therapy for solid tumors

Optimising CAR T therapy for the treatment of solid tumors

The development of CAR design for tumor CAR-T cell therapy

Gene modification strategies for next-generation CAR T cells against solid cancers